Exploiting differential expression of the IL-7 receptor on memory T cells to modulate immune responses

Cytokine and Growth Factor Reviews

Volumn 25, Issue 4, 2014, Pages 391-401

  Zaunders, John J ^a,b   Lévy, Yves ^c,d,e,f   Seddiki, Nabila ^c,d,e  

^a ST VINCENT S HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c INSERM U955   (France)

^d FACULTÉ DE MÉDECINE   (France)

^e Vaccine Research Institute   (France)

^f HENRI MONDOR HOSPITAL   (France)

Author keywords

IL 7R therapy; T cell

Indexed keywords

INTERLEUKIN 2; INTERLEUKIN 7; INTERLEUKIN 7 RECEPTOR; IL7 PROTEIN, HUMAN; INTERLEUKIN 7 RECEPTOR ALPHA;

CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CELL GROWTH; CELL SURVIVAL; CYTOKINE PRODUCTION; DOWN REGULATION; DRUG MECHANISM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOMODULATION; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE PROLIFERATION; LYMPHOCYTOPENIA; MELANOMA; MEMORY T LYMPHOCYTE; NONHUMAN; PROTEIN EXPRESSION; SHORT SURVEY; SIGNAL TRANSDUCTION; BIOSYNTHESIS; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; NEOPLASMS; REGULATORY T LYMPHOCYTE;

HUMANS; IMMUNOLOGIC MEMORY; INTERLEUKIN-7; INTERLEUKIN-7 RECEPTOR ALPHA SUBUNIT; LYMPHOCYTE ACTIVATION; LYMPHOPENIA; NEOPLASMS; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, REGULATORY;

EID: 84908021057     PISSN: 13596101     EISSN: 18790305     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2014.07.012     Document Type: Short Survey

References (132)

1. Jiang Q., Li W.Q., Aiello F.B., Mazzucchelli R., Asefa B., Khaled A.R., et al. Cell biology of IL-7, a key lymphotrophin. Cytokine Growth Factor Rev 2005, 16:513-533.
2. Borghesi L.A., Yamashita Y., Kincade P.W. Heparan sulfate proteoglycans mediate interleukin-7-dependent B lymphopoiesis. Blood 1999, 93:140-148.
3. Napolitano L.A., Grant R.M., Deeks S.G., Schmidt D., De Rosa S.C., Herzenberg L.A., et al. Increased production of IL-7 accompanies HIV-1-mediated T-cell depletion: implications for T-cell homeostasis. Nat Med 2001, 7:73-79.
4. Sasson S.C., Zaunders J.J., Kelleher A.D. The IL-7/IL-7 receptor axis: understanding its central role in T-cell homeostasis and the challenges facing its utilization as a novel therapy. Curr Drug Targets 2006, 7:1571-1582.
5. Zamisch M., Moore-Scott B., Su D.M., Lucas P.J., Manley N., Richie E.R. Ontogeny and regulation of IL-7-expressing thymic epithelial cells. J Immunol 2005, 174:60-67.
6. Shitara S., Hara T., Liang B., Wagatsuma K., Zuklys S., Hollander G.A., et al. IL-7 produced by thymic epithelial cells plays a major role in the development of thymocytes and TCRgammadelta+ intraepithelial lymphocytes. J Immunol 2013, 190:6173-6179.
7. Kim G.Y., Hong C., Park J.H. Seeing is believing: illuminating the source of in vivo interleukin-7. Immune Netw. 2011, 11:1-10.
8. Link A., Vogt T.K., Favre S., Britschgi M.R., Acha-Orbea H., Hinz B., et al. Fibroblastic reticular cells in lymph nodes regulate the homeostasis of naive T cells. Nat Immunol 2007, 8:1255-1265.
9. Goodwin R.G., Friend D., Ziegler S.F., Jerzy R., Falk B.A., Gimpel S., et al. Cloning of the human and murine interleukin-7 receptors: demonstration of a soluble form and homology to a new receptor superfamily. Cell 1990, 60:941-951.
10. Puel A., Ziegler S.F., Buckley R.H., Leonard W.J. Defective IL7R expression in T(-)B(+)NK(+) severe combined immunodeficiency. Nat Genet 1998, 20:394-397.
11. Fry T.J., Mackall C.L. The many faces of IL-7: from lymphopoiesis to peripheral T cell maintenance. J Immunol 2005, 174:6571-6576.
12. Seddiki N., Santner-Nanan B., Martinson J., Zaunders J., Sasson S., Landay A., et al. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med 2006, 203:1693-1700.
13. Seddiki N., Santner-Nanan B., Tangye S.G., Alexander S.I., Solomon M., Lee S., et al. Persistence of naive CD45RA+ regulatory T cells in adult life. Blood 2006, 107:2830-2838.
14. Carpino N., Thierfelder W.E., Chang M.S., Saris C., Turner S.J., Ziegler S.F., et al. Absence of an essential role for thymic stromal lymphopoietin receptor in murine B-cell development. Mol Cell Biol 2004, 24:2584-2592.
15. Larson R.P., Comeau M.R., Ziegler S.F. Cutting edge: allergen-specific CD4 T cells respond indirectly to thymic stromal lymphopoietin to promote allergic responses in the skin. J Immunol 2013, 190:4474-4477.
16. Fry T.J., Mackall C.L. Interleukin-7: from bench to clinic. Blood 2002, 99:3892-3904.
17. Osborne L.C., Dhanji S., Snow J.W., Priatel J.J., Ma M.C., Miners M.J., et al. Impaired CD8 T cell memory and CD4 T cell primary responses in IL-7R alpha mutant mice. J Exp Med 2007, 204:619-631.
18. Carrette F., Surh C.D. IL-7 signaling and CD127 receptor regulation in the control of T cell homeostasis. Semin Immunol 2012, 24:209-217.
19. Cheng J., Kane L.P. Global identification of genes and pathways regulated by Akt during activation of T helper cells. F1000 Res 2013, 2:109.
20. Feng X., Wang H., Takata H., Day T.J., Willen J., Hu H. Transcription factor Foxp1 exerts essential cell-intrinsic regulation of the quiescence of naive T cells. Nat Immunol 2011, 12:544-550.
21. Jacobs S.R., Michalek R.D., Rathmell J.C. IL-7 is essential for homeostatic control of T cell metabolism in vivo. J Immunol 2010, 184:3461-3469.
22. MacIver N.J., Michalek R.D., Rathmell J.C. Metabolic regulation of T lymphocytes. Annu Rev Immunol 2013, 31:259-283.
23. Surh C.D., Sprent J. Homeostasis of naive and memory T cells. Immunity 2008, 29:848-862.
24. Soares M.V., Borthwick N.J., Maini M.K., Janossy G., Salmon M., Akbar A.N. IL-7-dependent extrathymic expansion of CD45RA+ T cells enables preservation of a naive repertoire. J Immunol 1998, 161:5909-5917.
25. Geginat J., Sallusto F., Lanzavecchia A. Cytokine-driven proliferation and differentiation of human naive, central memory, and effector memory CD4(+) T cells. J Exp Med 2001, 194:1711-1719.
26. Brenchley J.M., Douek D.C., Ambrozak D.R., Chatterji M., Betts M.R., Davis L.S., et al. Expansion of activated human naive T-cells precedes effector function. Clin Exp Immunol 2002, 130:432-440.
27. Sasson S.C., Zaunders J.J., Zanetti G., King E.M., Merlin K.M., Smith D.E., et al. Increased plasma interleukin-7 level correlates with decreased CD127 and increased CD132 extracellular expression on T cell subsets in patients with HIV-1 infection. J Infect Dis 2006, 193:505-514.
28. Kimura M.Y., Pobezinsky L.A., Guinter T.I., Thomas J., Adams A., Park J.H., et al. IL-7 signaling must be intermittent, not continuous, during CD8(+) T cell homeostasis to promote cell survival instead of cell death. Nat Immunol 2013, 14:143-151.
29. Fry T.J., Moniuszko M., Creekmore S., Donohue S.J., Douek D.C., Giardina S., et al. IL-7 therapy dramatically alters peripheral T-cell homeostasis in normal and SIV-infected nonhuman primates. Blood 2003, 101:2294-2299.
30. Park J.H., Yu Q., Erman B., Appelbaum J.S., Montoya-Durango D., Grimes H.L., et al. Suppression of IL7Ralpha transcription by IL-7 and other prosurvival cytokines: a novel mechanism for maximizing IL-7-dependent T cell survival. Immunity 2004, 21:289-302.
31. Schluns K.S., Lefrancois L. Cytokine control of memory T-cell development and survival. Nat Rev Immunol 2003, 3:269-279.
32. Pellegrini M., Bouillet P., Robati M., Belz G.T., Davey G.M., Strasser A. Loss of Bim increases T cell production and function in interleukin 7 receptor-deficient mice. J Exp Med 2004, 200:1189-1195.
33. Toe J.G., Pellegrini M., Mak T.W. Promoting immunity during chronic infection-the therapeutic potential of common gamma-chain cytokines. Mol Immunol 2013, 56:38-47.
34. Opferman J.T., Letai A., Beard C., Sorcinelli M.D., Ong C.C., Korsmeyer S.J. Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1. Nature 2003, 426:671-676.
35. Kaech S.M., Cui W. Transcriptional control of effector and memory CD8+ T cell differentiation. Nat Rev Immunol 2012, 12:749-761.
36. Sakaguchi S. Naturally arising Foxp3-expressing CD25+ CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 2005, 6:345-352.
37. Kaech S.M., Tan J.T., Wherry E.J., Konieczny B.T., Surh C.D., Ahmed R. Selective expression of the interleukin 7 receptor identifies effector CD8 T cells that give rise to long-lived memory cells. Nat Immunol 2003, 4:1191-1198.
38. Joshi N.S., Cui W., Chandele A., Lee H.K., Urso D.R., Hagman J., et al. Inflammation directs memory precursor and short-lived effector CD8(+) T cell fates via the graded expression of T-bet transcription factor. Immunity 2007, 27:281-295.
39. Yu S., Zhou X., Hsiao J.J., Yu D., Saunders T.L., Xue H.H. Fidelity of a BAC-EGFP transgene in reporting dynamic expression of IL-7Ralpha in T cells. Transgenic Res 2012, 21:201-215.
40. Xue H.H., Bollenbacher J., Rovella V., Tripuraneni R., Du Y.B., Liu C.Y., et al. GA binding protein regulates interleukin 7 receptor alpha-chain gene expression in T cells. Nat Immunol 2004, 5:1036-1044.
41. Grenningloh R., Tai T.S., Frahm N., Hongo T.C., Chicoine A.T., Brander C., et al. Ets-1 maintains IL-7 receptor expression in peripheral T cells. J Immunol 2011, 186:969-976.
42. Chandele A., Joshi N.S., Zhu J., Paul W.E., Leonard W.J., Kaech S.M. Formation of IL-7Ralphahigh and IL-7Ralphalow CD8 T cells during infection is regulated by the opposing functions of GABPalpha and Gfi-1. J Immunol 2008, 180:5309-5319.
43. Joshi N.S., Kaech S.M. Effector CD8 T cell development: a balancing act between memory cell potential and terminal differentiation. J Immunol 2008, 180:1309-1315.
44. Banerjee A., Gordon S.M., Intlekofer A.M., Paley M.A., Mooney E.C., Lindsten T., et al. Cutting edge: the transcription factor eomesodermin enables CD8+ T cells to compete for the memory cell niche. J Immunol 2010, 185:4988-4992.
45. Knox J.J., Cosma G.L., Betts M.R., McLane L.M. Characterization of T-bet and eomes in peripheral human immune cells. Front Immunol 2014, 5:217.
46. Cimmino L., Martins G.A., Liao J., Magnusdottir E., Grunig G., Perez R.K., et al. Blimp-1 attenuates Th1 differentiation by repression of ifng, tbx21, and bcl6 gene expression. J Immunol 2008, 181:2338-2347.
47. Rutishauser R.L., Martins G.A., Kalachikov S., Chandele A., Parish I.A., Meffre E., et al. Transcriptional repressor Blimp-1 promotes CD8(+) T cell terminal differentiation and represses the acquisition of central memory T cell properties. Immunity 2009, 31:296-308.
48. Kallies A., Xin A., Belz G.T., Nutt S.L. Blimp-1 transcription factor is required for the differentiation of effector CD8(+) T cells and memory responses. Immunity 2009, 31:283-295.
49. Shin H., Blackburn S.D., Intlekofer A.M., Kao C., Angelosanto J.M., Reiner S.L., et al. A role for the transcriptional repressor Blimp-1 in CD8(+) T cell exhaustion during chronic viral infection. Immunity 2009, 31:309-320.
50. Seddiki N., Phetsouphanh C., Swaminathan S., Xu Y., Rao S., Li J., et al. The microRNA-9/B-lymphocyte-induced maturation protein-1/IL-2 axis is differentially regulated in progressive HIV infection. Eur J Immunol 2013, 43:510-520.
51. Crotty S. Follicular helper CD4 T cells (TFH). Annu Rev Immunol 2011, 29:621-663.
52. Xu Y., Weatherall C., Bailey M., Alcantara S., De Rose R., Estaquier J., et al. Simian immunodeficiency virus infects follicular helper CD4 T cells in lymphoid tissues during pathogenic infection of pigtail macaques. J Virol 2013, 87:3760-3773.
53. Crotty S., Johnston R.J., Schoenberger S.P. Effectors and memories: Bcl-6 and Blimp-1 in T and B lymphocyte differentiation. Nat Immunol 2010, 11:114-120.
54. Ji Y., Pos Z., Rao M., Klebanoff C.A., Yu Z., Sukumar M., et al. Repression of the DNA-binding inhibitor Id3 by Blimp-1 limits the formation of memory CD8+ T cells. Nat Immunol 2011, 12:1230-1237.
55. Yang C.Y., Best J.A., Knell J., Yang E., Sheridan A.D., Jesionek A.K., et al. The transcriptional regulators Id2 and Id3 control the formation of distinct memory CD8+ T cell subsets. Nat Immunol 2011, 12:1221-1229.
56. Maruyama T., Li J., Vaque J.P., Konkel J.E., Wang W., Zhang B., et al. Control of the differentiation of regulatory T cells and T(H)17 cells by the DNA-binding inhibitor Id3. Nat Immunol 2011, 12:86-95.
57. Kim M.V., Ouyang W., Liao W., Zhang M.Q., Li M.O. The transcription factor Foxo1 controls central-memory CD8+ T cell responses to infection. Immunity 2013, 39:286-297.
58. Hess Michelini R., Doedens A.L., Goldrath A.W., Hedrick S.M. Differentiation of CD8 memory T cells depends on Foxo1. J Exp Med 2013, 210:1189-1200.
59. Dejean A.S., Hedrick S.M., Kerdiles Y.M. Highly specialized role of Forkhead box O transcription factors in the immune system. Antioxid Redox Signal 2011, 14:663-674.
60. Hu G., Chen J. A genome-wide regulatory network identifies key transcription factors for memory CD8(+) T-cell development. Nat Commun 2013, 4:2830.
61. Arsenio J., Kakaradov B., Metz P.J., Kim S.H., Yeo G.W., Chang J.T. Early specification of CD8+ T lymphocyte fates during adaptive immunity revealed by single-cell gene-expression analyses. Nat Immunol 2014, 15:365-372.
62. Kurachi M., Barnitz R.A., Yosef N., Odorizzi P.M., DiIorio M.A., Lemieux M.E., et al. The transcription factor BATF operates as an essential differentiation checkpoint in early effector CD8+ T cells. Nat Immunol 2014, 15:373-383.
63. Dong H., Franklin N.A., Roberts D.J., Yagita H., Glennie M.J., Bullock T.N. CD27 stimulation promotes the frequency of IL-7 receptor-expressing memory precursors and prevents IL-12-mediated loss of CD8(+) T cell memory in the absence of CD4(+) T cell help. J Immunol 2012, 188:3829-3838.
64. Franchimont D., Galon J., Vacchio M.S., Fan S., Visconti R., Frucht D.M., et al. Positive effects of glucocorticoids on T cell function by up-regulation of IL-7 receptor alpha. J Immunol 2002, 168:2212-2218.
65. Ligons D.L., Tuncer C., Linowes B.A., Akcay I.M., Kurtulus S., Deniz E., et al. CD8 lineage-specific regulation of interleukin-7 receptor expression by the transcriptional repressor Gfi1. J Biol Chem 2012, 287:34386-34399.
66. Egawa T., Tillman R.E., Naoe Y., Taniuchi I., Littman D.R. The role of the Runx transcription factors in thymocyte differentiation and in homeostasis of naive T cells. J Exp Med 2007, 204:1945-1957.
67. Kim H.R., Hwang K.A., Kim K.C., Kang I. Down-regulation of IL-7Ralpha expression in human T cells via DNA methylation. J Immunol 2007, 178:5473-5479.
68. Magri M., Yatim A., Benne C., Balbo M., Henry A., Serraf A., et al. Notch ligands potentiate IL-7-driven proliferation and survival of human thymocyte precursors. Eur J Immunol 2009, 39:1231-1240.
69. Yatim A., Benne C., Sobhian B., Laurent-Chabalier S., Deas O., Judde J.G., et al. NOTCH1 nuclear interactome reveals key regulators of its transcriptional activity and oncogenic function. Mol Cell 2012, 48:445-458.
70. Appay V., Zaunders J.J., Papagno L., Sutton J., Jaramillo A., Waters A., et al. Characterization of CD4(+) CTLs ex vivo. J Immunol 2002, 168:5954-5958.
71. Zaunders J.J., Munier M.L., Kaufmann D.E., Ip S., Grey P., Smith D., et al. Early proliferation of CCR5+ CD38+++ antigen-specific CD4+ Th1 effector cells during primary HIV-1 infection. Blood 2005, 106:1660-1667.
72. Zaunders J.J., Ip S., Munier M.L., Kaufmann D.E., Suzuki K., Brereton C., et al. Infection of CD127+(interleukin-7 receptor+) CD4+ cells and overexpression of CTLA-4 are linked to loss of antigen-specific CD4 T cells during primary human immunodeficiency virus type 1 infection. J Virol 2006, 80:10162-10172.
73. Zaunders J.J., Dyer W.B., Munier M.L., Ip S., Liu J., Amyes E., et al. CD127+ CCR5+ CD38+++ CD4+ Th1 effector cells are an early component of the primary immune response to vaccinia virus and precede development of interleukin-2+ memory CD4+ T cells. J Virol 2006, 80:10151-10161.
74. Miller J.D., van der Most R.G., Akondy R.S., Glidewell J., Albot S., Masopust D., et al. Human effector and memory CD8+T cell responses to smallpox and yellow fever vaccines. Immunity 2008, 28:710-722.
75. Plumb A.W., Patton D.T., Seo J.H., Loveday E.K., Jean F., Ziegler S.F., et al. Interleukin-7, but not thymic stromal lymphopoietin, plays a key role in the T cell response to influenza A virus. PLoS One 2012, 7:e50199.
76. Mueller S.N., Gebhardt T., Carbone F.R., Heath W.R. Memory T cell subsets, migration patterns, and tissue residence. Annu Rev Immunol 2013, 31:137-161.
77. Doody G.M., Care M.A., Burgoyne N.J., Bradford J.R., Bota M., Bonifer C., et al. An extended set of PRDM1/BLIMP1 target genes links binding motif type to dynamic repression. Nucleic Acids Res 2010, 38:5336-5350.
78. Shin H.M., Kapoor V.N., Guan T., Kaech S.M., Welsh R.M., Berg L.J. Epigenetic modifications induced by Blimp-1 Regulate CD8(+) T cell memory progression during acute virus infection. Immunity 2013, 39:661-675.
79. Dunham R.M., Cervasi B., Brenchley J.M., Albrecht H., Weintrob A., Sumpter B., et al. CD127 and CD25 expression defines CD4+ T cell subsets that are differentially depleted during HIV infection. J Immunol 2008, 180:5582-5592.
80. Sereti I., Dunham R.M., Spritzler J., Aga E., Proschan M.A., Medvik K., et al. IL-7 administration drives T cell-cycle entry and expansion in HIV-1 infection. Blood 2009, 113:6304-6314.
81. Levy Y., Lacabaratz C., Weiss L., Viard J.P., Goujard C., Lelievre J.D., et al. Enhanced T cell recovery in HIV-1-infected adults through IL-7 treatment. J Clin Invest 2009, 119:997-1007.
82. Sereti I., Estes J.D., Thompson W.L., Morcock D.R., Fischl M.A., Croughs T., et al. Decreases in colonic and systemic inflammation in chronic HIV infection after IL-7 administration. PLoS Pathog 2014, 10:e1003890.
83. Kang J., Coles M. IL-7: the global builder of the innate lymphoid network and beyond, one niche at a time. Semin Immunol 2012, 24:190-197.
84. Rosenberg S.A., Sportes C., Ahmadzadeh M., Fry T.J., Ngo L.T., Schwarz S.L., et al. IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells. J Immunother 2006, 29:313-319.
85. Sereti I., Anthony K.B., Martinez-Wilson H., Lempicki R., Adelsberger J., Metcalf J.A., et al. IL-2 induced CD4+ T cell expansion in HIV-infected patients is associated with long-term decreases in T cell proliferation. Blood 2004, 104:775-780.
86. Weiss L., Letimier F.A., Carriere M., Maiella S., Donkova-Petrini V., Targat B., et al. In vivo expansion of naive and activated CD4+ CD25+ FOXP3+ regulatory T cell populations in interleukin-2-treated HIV patients. Proc Natl Acad Sci USA 2010, 107:10632-10637.
87. Abrams D., Levy Y., Losso M.H., Babiker A., Collins G., Cooper D.A., et al. Interleukin-2 therapy in patients with HIV infection. N Engl J Med 2009, 361:1548-1559.
88. Carcelain G., Autran B. Immune interventions in HIV infection. Immunol Rev 2013, 254:355-371.
89. Levy Y., Sereti I., Tambussi G., Routy J.P., Lelievre J.D., Delfraissy J.F., et al. Effects of recombinant human interleukin 7 on T-cell recovery and thymic output in HIV-infected patients receiving antiretroviral therapy: results of a phase I/IIa randomized, placebo-controlled, multicenter study. Clin Infect Dis 2012, 55:291-300.
90. Vandergeeten C., Fromentin R., DaFonseca S., Lawani M.B., Sereti I., Lederman M.M., et al. Interleukin-7 promotes HIV persistence during antiretroviral therapy. Blood 2013, 121:4321-4329.
91. Katlama C., Deeks S.G., Autran B., Martinez-Picado J., van Lunzen J., Rouzioux C., et al. Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs. Lancet 2013, 381:2109-2117.
92. Thiebaut R., Drylewicz J., Prague M., Lacabaratz C., Beq S., Jarne A., et al. Quantifying and predicting the effect of exogenous interleukin-7 on CD4+ T cells in HIV-1 infection. PLoS Comput Biol 2014, 10:e1003630.
93. Perales M.A., Goldberg J.D., Yuan J., Koehne G., Lechner L., Papadopoulos E.B., et al. Recombinant human interleukin-7 (CYT107) promotes T-cell recovery after allogeneic stem cell transplantation. Blood 2012, 120:4882-4891.
94. Toubert A. IL-7 earns her ticket in allo-HSCT. Blood 2012, 120:4669-4770.
95. Hotchkiss R.S., Monneret G., Payen D. Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach. Lancet Infect Dis 2013, 13:260-268.
96. Melchionda F., Fry T.J., Milliron M.J., McKirdy M.A., Tagaya Y., Mackall C.L. Adjuvant IL-7 or IL-15 overcomes immunodominance and improves survival of the CD8+ memory cell pool. J Clin Invest 2005, 115:1177-1187.
97. Colombetti S., Levy F., Chapatte L. IL-7 adjuvant treatment enhances long-term tumor-antigen-specific CD8+T-cell responses after immunization with recombinant lentivector. Blood 2009, 113:6629-6637.
98. Pellegrini M., Calzascia T., Elford A.R., Shahinian A., Lin A.E., Dissanayake D., et al. Adjuvant IL-7 antagonizes multiple cellular and molecular inhibitory networks to enhance immunotherapies. Nat Med 2009, 15:528-536.
99. Pellegrini M., Calzascia T., Toe J.G., Preston S.P., Lin A.E., Elford A.R., et al. IL-7 engages multiple mechanisms to overcome chronic viral infection and limit organ pathology. Cell 2011, 144:601-613.
100. Nanjappa S.G., Walent J.H., Morre M., Suresh M. Effects of IL-7 on memory CD8 T cell homeostasis are influenced by the timing of therapy in mice. J Clin Invest 2008, 118:1027-1039.
101. Seo Y.B., Im S.J., Namkoong H., Kim S.W., Choi Y.W., Kang M.C., et al. Crucial role of IL-7 in the development of T follicular helper cells as well as the induction of humoral immunity. J Virol 2014.
102. Vanneman M., Dranoff G. Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer 2012, 12:237-251.
103. Parkinson D.R., Abrams J.S., Wiernik P.H., Rayner A.A., Margolin K.A., Van Echo D.A., et al. Interleukin-2 therapy in patients with metastatic malignant melanoma: a phase II study. J Clin Oncol: Off J Am Soc Clin Oncol 1990, 8:1650-1656.
104. Gou H.F., Huang J., Shi H.S., Chen X.C., Wang Y.S. Chemo-immunotherapy with oxaliplatin and interleukin-7 inhibits colon cancer metastasis in mice. PLoS One 2014, 9:e85789.
105. Mondino A., Dardalhon V., Hess Michelini R., Loisel-Meyer S., Taylor N. Redirecting the immune response: role of adoptive T cell therapy. Hum Gene Ther 2010, 21:533-541.
106. Gattinoni L., Klebanoff C.A., Restifo N.P. Paths to stemness: building the ultimate antitumour T cell. Nat Rev Cancer 2012, 12:671-684.
107. Cha E., Graham L., Manjili M.H., Bear H.D. IL-7+ IL-15 are superior to IL-2 for the ex vivo expansion of 4T1 mammary carcinoma-specific T cells with greater efficacy against tumors in vivo. Breast Cancer Res Treat 2010, 122:359-369.
108. Yang S., Ji Y., Gattinoni L., Zhang L., Yu Z., Restifo N.P., et al. Modulating the differentiation status of ex vivo-cultured anti-tumor T cells using cytokine cocktails. Cancer Immunol, Immunother: CII 2013, 62:727-736.
109. Loh Y.H., Hartung O., Li H., Guo C., Sahalie J.M., Manos P.D., et al. Reprogramming of T cells from human peripheral blood. Cell Stem Cell 2010, 7:15-19.
110. Staerk J., Dawlaty M.M., Gao Q., Maetzel D., Hanna J., Sommer C.A., et al. Reprogramming of human peripheral blood cells to induced pluripotent stem cells. Cell Stem Cell 2010, 7:20-24.
111. Seki T., Yuasa S., Oda M., Egashira T., Yae K., Kusumoto D., et al. Generation of induced pluripotent stem cells from human terminally differentiated circulating T cells. Cell Stem Cell 2010, 7:11-14.
112. Serwold T., Hochedlinger K., Swindle J., Hedgpeth J., Jaenisch R., Weissman I.L. T-cell receptor-driven lymphomagenesis in mice derived from a reprogrammed T cell. Proc Natl Acad Sci U S A 2010, 107:18939-18943.
113. Marr L.A., Gilham D.E., Campbell J.D., Fraser A.R. Immunology in the clinic review series; focus on cancer: double trouble for tumours: bi-functional and redirected T cells as effective cancer immunotherapies. Clin Exp Immunol 2012, 167:216-225.
114. Perna S.K., Pagliara D., Mahendravada A., Liu H., Brenner M.K., Savoldo B., et al. Interleukin-7 mediates selective expansion of tumor-redirected cytotoxic T lymphocytes (CTLs) without enhancement of regulatory T-cell inhibition. Clin Cancer Res: Off J Am Assoc Cancer Res 2014, 20:131-139.
115. Harari A., Bellutti Enders F., Cellerai C., Bart P.A., Pantaleo G. Distinct profiles of cytotoxic granules in memory CD8 T cells correlate with function, differentiation stage, and antigen exposure. J Virol 2009, 83:2862-2871.
116. Chung B., Dudl E.P., Min D., Barsky L., Smiley N., Weinberg K.I. Prevention of graft-versus-host disease by anti IL-7Ralpha antibody. Blood 2007, 110:2803-2810.
117. Mai H.L., Boeffard F., Longis J., Danger R., Martinet B., Haspot F., et al. IL-7 receptor blockade following T cell depletion promotes long-term allograft survival. J Clin Invest 2014, 124:1723-1733.
118. Dooms H. Interleukin-7: fuel for the autoimmune attack. J Autoimmun 2013, 45:40-48.
119. Teutsch S.M., Booth D.R., Bennetts B.H., Heard R.N., Stewart G.J. Identification of 11 novel and common single nucleotide polymorphisms in the interleukin-7 receptor-alpha gene and their associations with multiple sclerosis. Eur J Hum Genet: EJHG 2003, 11:509-515.
120. Gregory S.G., Schmidt S., Seth P., Oksenberg J.R., Hart J., Prokop A., et al. Interleukin 7 receptor alpha chain (IL7R) shows allelic and functional association with multiple sclerosis. Nat Genet 2007, 39:1083-1091.
121. Lundmark F., Duvefelt K., Iacobaeus E., Kockum I., Wallstrom E., Khademi M., et al. Variation in interleukin 7 receptor alpha chain (IL7R) influences risk of multiple sclerosis. Nat Genet 2007, 39:1108-1113.
122. Hafler D.A., Compston A., Sawcer S., Lander E.S., Daly M.J., et al. Risk alleles for multiple sclerosis identified by a genomewide study, International Multiple Sclerosis Genetics C. N Engl J Med 2007, 357:851-862.
123. Lundstrom W., Highfill S., Walsh S.T., Beq S., Morse E., Kockum I., et al. Soluble IL7Ralpha potentiates IL-7 bioactivity and promotes autoimmunity. Proc Natl Acad Sci U S A 2013, 110:E1761-E1770.
124. Gonzalez-Quintial R., Lawson B.R., Scatizzi J.C., Craft J., Kono D.H., Baccala R., et al. Systemic autoimmunity and lymphoproliferation are associated with excess IL-7 and inhibited by IL-7Ralpha blockade. PLoS One 2011, 6:e27528.
125. Penaranda C., Kuswanto W., Hofmann J., Kenefeck R., Narendran P., Walker L.S., et al. IL-7 receptor blockade reverses autoimmune diabetes by promoting inhibition of effector/memory T cells. Proc Natl Acad Sci U S A 2012, 109:12668-12673.
126. Lee L.F., Logronio K., Tu G.H., Zhai W., Ni I., Mei L., et al. Anti-IL-7 receptor-alpha reverses established type 1 diabetes in nonobese diabetic mice by modulating effector T-cell function. Proc Natl Acad Sci U S A 2012, 109:12674-12679.
127. Nemoto Y., Kanai T., Takahara M., Oshima S., Nakamura T., Okamoto R., et al. Bone marrow-mesenchymal stem cells are a major source of interleukin-7 and sustain colitis by forming the niche for colitogenic CD4 memory T cells. Gut 2013, 62:1142-1152.
128. Danese S., Rutella S., Vetrano S. Mesenchymal stromal cells in inflammatory bowel disease: conspirators within the 'colitogenic niche'?. Gut 2013, 62:1098-1099.
129. Wuest T.Y., Willette-Brown J., Durum S.K., Hurwitz A.A. The influence of IL-2 family cytokines on activation and function of naturally occurring regulatory T cells. J Leukoc Biol 2008, 84:973-980.
130. Younas M., Hue S., Lacabaratz C., Guguin A., Wiedemann A., Surenaud M., et al. IL-7 modulates in vitro and in vivo human memory T regulatory cell functions through the CD39/ATP axis. J Immunol 2013, 191:3161-3168.
131. Kamimura D., Bevan M.J. Endoplasmic reticulum stress regulator XBP-1 contributes to effector CD8+ T cell differentiation during acute infection. J Immunol 2008, 181:5433-5441.
132. DeKoter R.P., Schweitzer B.L., Kamath M.B., Jones D., Tagoh H., Bonifer C., et al. Regulation of the interleukin-7 receptor alpha promoter by the Ets transcription factors PU.1 and GA-binding protein in developing B cells. J Biol Chem 2007, 282:14194-14204.